Formulation and Optimization of Trandolapril Oro-dispersible Tablets using the Quality by Design (QbD) Approach

被引:1
|
作者
Kumar, Ganesh [1 ]
Bhatt, Meenakshi [2 ]
机构
[1] Coll Pharm, Shivalik Campus, Dehra Dun, Uttrakhand, India
[2] SGRR Univ, Sch Pharmaceut Sci, Dehra Dun, Uttrakhand, India
关键词
Oro-dispersible tablet; crospovidone; microcrystalline cellulose; quality by design; disintegration; friability; PRODUCTS;
D O I
10.2174/1570180819666220429153102
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Introduction This study aims to use a Quality by Design (QbD) approach to formulate and optimize Trandolapriloro-dispersible tablets. The central composite design tool was utilized to assess the scientific understanding of independent input variables and output responses to construct a design space for regulatory flexibility. Oro-dispersible Tablets (ODT) can also be used to deliver drugs directly to the oral mucosa, bypassing first-pass hepatic metabolism and potentially accelerating the process. Methodology The concentrations of super disintegrant and dry compressible binder were selected as independent variables. Disintegration time in seconds and % friability was selected as dependent variables. Polynomial equations were used to predict the quantitative effect of independent variables at various levels on response variables. Results and Discussion The pre-compression parameters suggested that the flow characteristics were quite excellent. All tablets prepared in the above experiments were evaluated for pharmaco-technical properties and found to be within the required limits using the direct compression method. The angle of repose of the dry blends from each formulation batch (F1 to F9) ranged from 29.03 & DEG; to 33.67 & DEG;. All formulation batches had a loose bulk density of 0.31 & PLUSMN; 0.07 to 0.37 & PLUSMN; 0.91 g/cm(3) and a tapped density of 0.41 & PLUSMN; 0.02 to 0.46 & PLUSMN; 0.16 g/cm(3), respectively. The compressibility index was determined to be between 1.65 & PLUSMN; 0.17 to 19.93 & PLUSMN; 0.47 . Hausner's ratio was between 1.14 & PLUSMN; 0.88 to 1.19 & PLUSMN; 0.32. The thickness of the tablets ranged from 2.07 & PLUSMN; 0.54 to 2.52 & PLUSMN; 0.12 mm. The tablets were found to have a hardness of 3.08 & PLUSMN; 0.14 to 3.67 & PLUSMN; 0.41 kg/cm(2). The weight of the tablets prepared ranged from 50 & PLUSMN; 0.09 to 52 & PLUSMN; 0.56 mg on average. Tablet friability was 0.52 & PLUSMN; 0.54 to 0.83 & PLUSMN; 0.10%, and the disintegration time ranged between 27 and 58 seconds. All of these parameters were found under the acceptable limit of pharmacopoeias. The increase of Crospovidone concentration decreased the disintegration time and increased % friability. Whereas increasing the concentration of microcrystalline cellulose increased the disintegration time and decreased the % friability. Contour plots clarified the link between independent and dependent variables. The most cost-effective batch was chosen based on these plots within the desired range because the actual and projected values suggested by the full model were very close to each other; the statistical model is mathematically valid. Conclusion The results showed that the proposed design for developing trandolapriloro-dispersible tablets with optimal properties was effective.
引用
收藏
页码:1194 / 1203
页数:10
相关论文
共 50 条
  • [31] Formulation Development and Optimization of Fenoprofen Floating Tablet Using QbD Approach
    Sikarwar, Gaurav Singh
    Gupta, Mukesh Kumar
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL INVESTIGATION, 2024, 14 (01) : 76 - 88
  • [32] Implementation of Quality by Design (QbD) for development of bilayer tablets
    Simao, J.
    Chaudhary, S. A.
    Ribeiro, A. J.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 184
  • [33] A QbD Approach for the Formulation and Control of Triclabendazole in Uncoated Tablets: From Polymorphs to Drug Formulation
    Muzi, Lucas P.
    Antonio, Marina
    Maggio, Ruben M.
    PHARMACEUTICS, 2024, 16 (12)
  • [34] Topical oro-dispersible budesonide tablets for stricture prevention after near circumferential ESD for esophageal squamous cell cancer - a case report
    Mathies, Daniel
    Oyama, Tsuneo
    Steinbrueck, Ingo
    Dumoulin, Franz Ludwig
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (05): : 454 - 456
  • [35] FORMULATION OF ORODISPERSIBLE TABLETS CONTAINING PARACETAMOL AND THEIR IN VITRO CHARACTERIZATION - A QbD APPROACH
    Muntean, Andrei Catalin
    Negoi, Oana Iuliana
    Rus, Luca Liviu
    Vonica, Andreea Loredana
    Tomuta, Ioan
    FARMACIA, 2020, 68 (03) : 436 - 446
  • [36] Effectiveness and patient satisfaction with the new sildenafil oral suspension formulation compared to sildenafil oro-dispersible film: a real-life study
    Boeri, Luca
    Graps, Giorgio
    Zino, Ester
    Zago, Agnese
    Li Puma, Andrea
    Ciamarra, Fabio
    Cimmino, Antonio
    Parolin, Valentina
    Piccoli, Michela
    Gadda, Franco
    Montanari, Emanuele
    Albo, Giancarlo
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2025,
  • [37] Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product
    Pielenhofer, Jonas
    Meiser, Sophie Luise
    Gogoll, Karsten
    Ciciliani, Anna-Maria
    Denny, Mark
    Klak, Michael
    Lang, Berenice M. M.
    Staubach, Petra
    Grabbe, Stephan
    Schild, Hansjoerg
    Radsak, Markus P. P.
    Spahn-Langguth, Hilde
    Langguth, Peter
    PHARMACEUTICS, 2023, 15 (02)
  • [38] APPLICATION OF QUALITY BY DESIGN (QBD) IN FORMULATION DEVELOPMENT OF IMMEDIATE AND EXTENDED RELEASE BILAYERED TABLETS OF DEXTROMETHORPHAN AS A MODEL
    Nadeem, Mohd
    Babu, M. Suresh
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 1 (06): : 439 - 447
  • [39] Tailoring immediate release FDM 3D printed tablets using a quality by design (QbD) approach
    Than, Yee Mon
    Titapiwatanakun, Varin
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2021, 599
  • [40] Formulation and pharmaceutical development of quetiapine fumarate sustained release matrix tablets using a QbD approach
    Gavan, Alexandru
    Porfire, Alina
    Marina, Cristina
    Tomuta, Ioan
    ACTA PHARMACEUTICA, 2017, 67 (01) : 53 - 70